In its financial results for the first quarter of 2020 BioMarin Pharmaceutical Inc. states:

On November 14, 2019, the Company announced its third gene therapy candidate, BMN 331, for the treatment of HAE. BioMarin plans to build on its ever wider and deeper expertise in developing gene therapies for severe hemophilia A and phenylketonuria to improve efficiencies in the development process, and to optimize capsid and transgene design. The Company is monitoring developments surrounding COVID-19 but expects to begin IND-enabling studies in mid-2020.
(Source: BioMarin)